CSPC Wins China Trial Nod for Ultra-Long-Acting Post-Operative Pain Injection

CSPC Pharmaceutical Group ( (HK:1093) ) has issued an announcement.

CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials for its Ropivacaine Long-acting Injection, SYH9089, targeting post-operative pain management. The product is designed to provide ultra-long-acting analgesia of up to one week from a single dose, using the group’s long-acting delivery platform to improve adherence and reduce reliance on opioids and continuous analgesia devices.

Preclinical data indicate that SYH9089 shows no systemic toxicity or new target-organ damage and offers a significantly longer analgesic effect compared with existing ropivacaine injections, with a favorable safety and efficacy profile. The trial approval marks a key milestone for CSPC in the central nervous system field and, if successful, could position the company as a frontrunner in addressing China’s unmet need for extended post-operative pain control, with potential benefits for both patients and healthcare providers.

The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.70 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company focused on developing and manufacturing innovative therapies, including central nervous system and analgesic drugs, for the Chinese healthcare market. The group leverages proprietary long-acting drug delivery technologies to enhance treatment efficacy, safety, and patient adherence across its product portfolio.

YTD Price Performance: 19.93%

Average Trading Volume: 121,949,988

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$116.3B

For detailed information about 1093 stock, go to TipRanks’ Stock Analysis page.